Species differences in the in vitro metabolism of EGYT-475, a new antidepressant agent.
The metabolism of N-benzyl-piperazine-picolinyl fumarate (EGYT-475), a new antidepressant agent, was studied in rat and dog liver homogenate and microsomes. The metabolites were separated by HPLC technique. Quantitative analysis was performed using radioactive labelled form of EGYT-475. The metabolic pathways of EGYT-475 in both species involve hydrolysis in the piperazine-picolinyl part and oxidation of the benzyl group to benzoic acid. The rate of these transformations differs in the two species. The possibility of the formation of polar conjugates was also studied.